BBLN - BBLN STOCK NEWS

Babylon Holdings Limited (NYSE:BBLN) experienced significant trading activity on April 22, 2022, with over 45 times the average daily volume. This surge coincided with the expiration of a 6-month lock-up affecting approximately 230 million shares following its NYSE debut on October 22, 2021. The company reported no additional corporate developments related to this activity and reaffirmed its earlier guidance from the Q4 2021 earnings release.

Babylon will hold its Q1 2022 earnings call on May 12, 2022.

Babylon (NYSE: BBLN) will host a conference call on May 12, 2022, at 8:00 AM ET to discuss its first-quarter 2022 financial results. A press release with these results will be issued before the call. To join, U.S. participants can call 877-407-7994, U.K. participants 0 800 756 3429, and international participants +1 215-268-9868. Babylon, a leading digital healthcare firm, aims to make healthcare accessible worldwide, serving over 440k lives globally with high retention and satisfaction rates.

Babylon Holdings Limited (NYSE:BBLN) has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2021, with the SEC. The report is accessible on the Company's Investor Relations website. Babylon focuses on making healthcare accessible through its digital-first platform, managing over 440,000 lives globally as of 2022. The Company achieved significant user engagement with a 93% retention rate and completed approximately 5.2 million consultations in 2021. Shareholders can request a hard copy of the report via email.

Babylon (NYSE: BBLN) has integrated its AI-powered Symptom Checker into Higi's mobile app, expanding proactive health engagement for users. This integration follows Babylon's acquisition of Higi, enhancing their technology platform for thousands of U.S. app users. The Symptom Checker helps users understand their symptoms through an interactive interface, offering trusted health resources. This collaboration aims to empower consumers with health management tools and could attract future partnerships for Babylon, enhancing their competitive position in digital healthcare.

Babylon Holdings Limited (NYSE:BBLN) reported a remarkable revenue growth of over four times year-over-year, reaching $323 million in 2021. Monthly revenue exceeded $80 million in January 2022. The company projects a substantial increase in revenue for 2022, with guidance set between $900 million to $1 billion. Adjusted EBITDA improved significantly from (184)% in 2020 to (54)% in 2021, expected to further improve to around (30)% in 2022. Despite losses totaling $374.5 million in 2021, the company aims for profitability by 2025, supported by ongoing investments and expanding U.S. Value-Based Care membership.

Bartell Drugs, a subsidiary of Rite Aid Corporation (NYSE: RAD), has partnered with Higi, a subsidiary of Babylon (NYSE: BBLN), to introduce enhanced health self-screening stations across 50 Bartell's locations in the Puget Sound area. These stations provide free assessments for various health risks, including hypertension and diabetes, and promote health awareness and education. This initiative coincides with National Heart Month and builds on a five-year partnership between Rite Aid and Higi, aimed at empowering customers to manage their health more effectively.

Babylon (NYSE: BBLN) will host a conference call on March 10, 2022, at 8:00 AM ET to discuss its fourth quarter 2021 financial results. A press release detailing these results will be issued prior to the call. Babylon, a leading digital healthcare company, aims to provide accessible, affordable healthcare worldwide, currently serving approximately 24 million people. The firm’s advanced technology and clinical services support a global network across 15 countries, managing about 440,000 lives through its digital-first platform.

Babylon (NYSE: BBLN) has completed its acquisition of DayToDay Health, enhancing its digital healthcare offerings for members. This acquisition aims to provide targeted pre- and post-surgical care through DayToDay’s digital programs, significantly reducing rehospitalization rates to below 4% compared to the industry average of 15%. Babylon plans to integrate DayToDay’s services to improve patient experience and health outcomes. The collaboration is expected to leverage Babylon's AI capabilities and expand its healthcare reach globally.

Babylon announced significant growth, expecting January 2022 revenues to exceed $80 million, which has led to increased full-year guidance for 2022 between $900 million and $1 billion. This is a substantial increase from previous forecasts of $710 million, reflecting a projected tripling of 2021 revenues. The company attributed this growth to securing 88,000 new value-based care members, boosting total managed lives to over 440,000. Preliminary estimates for 2021 revenues are around $321 million.